Reduced CD48 expression was observed in primary ATLL cells and other aggressive peripheral T cell lymphomas, indicating its significance as a biomarker for NK-cell-associated immunotherapies.69 The gene discussed is CD48; the disease is adult T-cell leukemia/lymphoma.